Milestone: 50,000 Devices and Counting!
The aesthetic elite over at Classys, KOSDAQ: 214150, just pulled a rabbit out of their hat. They're approaching the slick 50,000 mark in device sales this year. That's a whole lot of machines beautifying folks across the globe. It's more than numbers though—it's the story of a company flexing its muscles in the global medical aesthetic market.
Leaning Into a Broader Portfolio
Gone are the days when Classys just hung its hat on high-intensity focused ultrasound (HIFU) and monopolar radiofrequency (MRF). Now, they’re diving into the deep end with an expanded lineup—microneedle radiofrequency (MNRF), laser systems, and dermabrasion devices. This isn’t just a game of numbers, it’s a strategic play to bolster their medium to long-term growth.
Strutting Around Global Markets
Export growth is nothing to sneeze at, either. For the first half of 2026, excluding those tricky Brazilian shipments, export sales puffed up by 29% year over year. Consumers are clearly biting into the Classys palette beyond just HIFU, which shows their product diversification gamble is paying off in spades across the board.
The Korean Base: A Stronghold
Back home in Korea, contributing around a quarter of total revenue, Classys is using it as a testing ground, ironing out the kinks before global rollouts. It ain’t just a sandbox; it’s a launchpad for new products and treatment protocols. They’re banking on this base to amplify their brand out there in the big bad world of skincare.
Financials: Cruising with Margins
Speaking of money matters, Classys ain’t slipping. Their revenue cracked KRW 192.7 billion in the first half—the coin's up 20% from last year. Operating margins strutted in at an impressive 50.8%, even with ongoing investments in global commercialization. In Europe, their reach is spreading into new territories like the UK and Bulgaria, nudging sales upwards. It’s a pretty diverse investment across the pond, if you ask me.
"The continued growth in cumulative global device sales demonstrates that Classys is steadily expanding its reach among medical professionals and patients worldwide," said Yugene Choi, Head of Investor Relations at Classys.
Building on Consumables and Cross-Selling
Now, these machines aren’t just one-time buys. They’ve got consumables tied to 'em, which means recurring revenue is a hefty slice of their pie. In the first half, consumables revenue hit KRW 80.2 billion—a 5.3% year-on-year and a meteoric 52.7% surge from 2024. The body shop ain't closing up anytime soon.
Eye on the Future
Classy's not sitting back though; they're primed for a product lineup that's set to keep shaking things up. With the Viclara launch in Europe, they'll lean on past relationships to wiggle past market entry obstacles and upsell like a pro. They’re already knee-deep in prepping for regulatory approvals and honing tailored marketing to regional tastes. From global congresses to education programs, they're pulling every trick to cement their foothold further.
All said and done, this isn’t just about aesthetics; it’s an odds-on bet that this company’s calculated maneuvers across products, markets, and technology will keep them sitting pretty for a while. For any investor out there, watch these moves closely—Classys is not just investing in beautifying faces but also in emboldening their bottom line.
